POSSIBILITIES OF METHORMINE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS: TEST OF TIME


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Type 2 diabetes mellitus (DM2) is an actual modern medical and social problem. The review article discusses the pathogenesis of the disease. The important role of insulin resistance as a key link in the development of DM2 is emphasized. Details of the mechanism of action of metformin, its glycemic and extra-glycemic effects, the place of the drug in modern diabetes therapy are considered.

Full Text

Restricted Access

About the authors

E. V Biryukova

Moscow State Medical Stomatological University n.a. A.I. Evdokimov

Email: lena@obsudim.ru
MD, Prof., MSMSU Moscow, Russia

I. V Solovyeva

Moscow State Medical Stomatological University n.a. A.I. Evdokimov

Moscow, Russia

N. M Platonova

Scientific Medical Research Center of Endocrinology

Moscow, Russia

References

  1. IDF http://www.diabetesatlas.org/
  2. Дедов И.И., Шестакова М.В. Сахарный диабет. 2007;3:55-7.
  3. Kooy A., de Jager J., Lehert P., et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch. Intern Med. 2009;169:616-25.
  4. Hemmingsen B., Lund S., Wetterslev J., Vaag A. Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur. J. Endocrinol. 2009;161:1-9.
  5. Meier M., Hummel M. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. Vasc. Health Risk Manag. 2009;5:859-71.
  6. Bailey C.J., Turner R.C. Metformin. N. Engl. J. Med. 1996;334:574-79.
  7. Rotella C.M., Monami M., Mannucci E. Metformin beyond diabetes: new life for an old drug. Curr. Diabet. Rev. 2006;2:307-15.
  8. Mann-Pehalver J.J., Martln-Timon I., Sevillano-Collantes C., Del Cahizo-Gomez F.J. Update on the treatment of type 2 diabetes mellitus. World J. Diabet. 2016;7(17):354-95. Doi: 10.4239/ wjd.v7.i17.354.
  9. Kinaan M., Ding H., Triggle C.R. Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium. Med. Princ. Pract. 2015;24:401-15. doi: 10.1159/000381643.
  10. Kirpichnikov D., McFarlane S.I., Sowers J.R. Metformin. An Update. Ann. Intern. Med. 2002;137:25-33.
  11. Godarzi M.O., Brier-Ash M. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabet. Obes. Metab. 2005;5:654-65.
  12. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-65.
  13. Rojas L.B.A., Gomes M.B. Metformin: an old but still the best treatment for type 2 diabetes Diabet. Metabolic. Syndrome. 2013;5:6. Doi. org/10.1186/1758-5996-5-6.
  14. Coutinho M., Gerstein H., Wang Y., Yusuf S. The relationship between glucose and incident cardiovascular events, a metaregression analysis of published data from 20 studies of 95783 individuals followed for 12,4 years. Diabet. Care. 1999;22:233-40.
  15. Coughlan K.A., Valentine R.J., Ruderman N.B., et al. AMPK activation: a therapeutic target for type 2 diabetes? Diabet. Metab. Syndr. Obes. 2014;7:241-53.
  16. Foretz M., He'brard S., Leclerc J., Zarrinpashneh E., Soty M., et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 2010;120:2355-69.
  17. Markowicz-Piasecka M., Huttune M.K., Lukasz M., et al. Is Metformin a Perfect Drug? Updates in Pharmacokinetics and Pharmacodynamics. Curr. Pharm. Des. 2017;23:1-19.
  18. Pryor R., Cabreiro F. Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem. J. 2015;471(3):307-22.
  19. Shinmura K., Negoro T., Shimizu S., et al. Metformin Modulates GLP-1- and GIP-Mediated Intracellular Signaling under Normoglycemic Conditions. Open J. Endocr. Metab. Dis. 2013;3:263-70.
  20. McCreight L.J., Bailey C.J., Pearson E.R. Metformin and the gastrointestinal tract. Diabet. 2016;59(3):426-35.
  21. Lien F., Berthier A., Bouchaert E., et al. Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. J. Clin. Invest. 2014;124:1037-51.
  22. Schwartz S.S., Epstein S., Corkey B.E., et al. The time is right for a new classification system for diabetes: rationale and implications of the ß-cell-centric classification schema. Diabet. Care. 2016;39:179-86.
  23. Мкртумян А.М., Бирюкова Е.В. Болезни сердца и сосудов. 2007;2:31-5.
  24. Berkowitz S.A., Krumme A.A., Avorn J. Initial choice of oral glucose-lowering medication for diabetes mellitus a patient-centered comparative effectiveness study. JAMA. Intern. Med. 2014;174(12):1955-62. Doi:10.1001/ jamainternmed.2014.5294.
  25. Malin S.K., Kashyap S.R Effects of metformin on weight loss: potential mechanisms. Current Opinion in Endocrinology, Diabet. Obes. 2014;21(5):323-29.
  26. Kim H.-J., Jin B.Y., Oh M.-J., Shin K.-H., ChoiS.-H., Kim D.-H. The effect of metformin on neuronal activity in the appetite-regulating brain regions of mice fed a high-fat diet during an anorectic period. Physiol. Behavior. 2016;154:184-19. Doi.org/10.1016/j.physbeh.2015.11.028.
  27. Malin S.K., Sangeeta R.K. Effects of metformin on weight loss: potential mechanisms. Current Opinion in Endocrinology, Diabet. Obes. 2014;21(5):323-9. Doi: 10.1097/ MED.0000000000000095.
  28. Chau-Van C., Gamba M., Salvi R., et al. Metformin Inhibits Adenosine 5'-Monophosphate-Activated Kinase Activation and Prevents Increases in Neuropeptide Y Expression in Cultured Hypothalamic Neurons. Endocrinol. 2007;148(2):507-11.
  29. Li Y., Xu S., Mihaylova M.M., et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell. Metab. 2011;13:376-88.
  30. Mamputu J.C., Wiernsperger N.F., Renier G.A. Antiatherogenic properties of metformin: the experimental evidence. Diabet. Metab. 2003;29:6S71-76.
  31. Ouslimani N., Mahrouf M., Peynet J., et al. Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin-like oxidized receptor 1. Metabolism. 2007;56(3):308-13.
  32. Chakraborty A., Chowdhury S., Bhattacharyya M. Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabet. Res. Clin. Pr. 2011;93:56-62.
  33. Johnson J.A., Majumdar S.R., Simpson S.H: Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabet. Care. 2002;25:2244-48.
  34. Kao J., Tobis J., Mc Clelland R.L. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am. J. Cardiol. 2004;93:1347-50. doi: 10.1016/j.amjcard.2004.02.028.
  35. Holden S.E., Jenkins-Jones S., Currie C.J. Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort Study. PLoS One. 2016;6;11(5):e0153594. Doi: 10.1371/ journal.pone.0153594.
  36. Lee H., Ko G. Effect of metformin on metabolic improvement and gut microbiota. Appl. Environ Microbiol. 2014;80:5935-43.
  37. Кожевников А.А., Раскина К.В., Мартынова Е.Ю. Тяхт А. Участие кишечной микробиоты в процессах метаболизма, старения и перспективы применения имеющихся данных в реальной клинической практике. РМЖ. «Медицинское обозрение» 2017;2:98-105.
  38. Decensi A., et al. Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev. Res. (Phila). 2010;3(11):1451-61.
  39. Coyle C., Cafferty F.H., Vale C., et al. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann. Oncol. 2016;27(12):2184-95.
  40. Kasznicki J., Sliwinska A., Drzewoski J. Metformin in cancer prevention and therapy. Ann. Transl. Med. 2014;2(6):57. doi: 10.3978/j.issn.2305-5839.2014.06.01.
  41. Topcu S., Tok D., Caliskan M. Metformin therapy improves coronary microvascular function in patient with polycystic ovary syndrom and insulin resistence. Clin. Endocrinol. (Oxf). 2006;65(1):75-80.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies